RxDoctor Payments Data

George Chidi, MD

Internal Medicine · Corona, CANPI 1396168944

Payments from drug & device makers

$1,391in general payments, 2019–2025

Across 78 payments — averaging $17.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$354
  • AstraZeneca$319
  • Abbott$229
  • Lilly USA, LLC$176
  • Kowa Pharmaceuticals America, Inc.$73
  • Novo Nordisk$65
  • plus $175 from 7 others

What the payments were for

  • Food & beverage$1,26691%
  • Education$1259%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,391 in reported general payments places this provider in the 75th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$39,146
Medicare patients
96
Services billed
412

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide123$158,470
JardianceEmpagliflozin69$75,751
JanuviaSitagliptin Phosphate37$33,888
FarxigaDapagliflozin Propanediol44$31,928
Synjardy XrEmpagliflozin/Metformin Hcl50$30,531
MounjaroTirzepatide24$24,889
EliquisApixaban18$16,007
RybelsusSemaglutide14$13,265
Rosuvastatin Calcium277$3,700
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate15$3,037
Lantus SolostarInsulin Glargine,hum.Rec.Anlog20$2,684
Gabapentin164$2,546
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide150$2,187
Albuterol Sulfate HfaAlbuterol Sulfate50$1,267
LantusInsulin Glargine,hum.Rec.Anlog15$1,183

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$65$171,735137 claims
Boehringer IngelheimJardiance, Synjardy Xr$354$106,283119 claims
AstraZenecaFarxiga$319$31,92844 claims
Lilly USA, LLCMounjaro$176$24,88924 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Corona

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →